STOCK TITAN

EDAP TMS SA - EDAP STOCK NEWS

Welcome to our dedicated page for EDAP TMS SA news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on EDAP TMS SA stock.

EDAP TMS SA (NASDAQ: EDAP) is a global leader in therapeutic ultrasound with over 30 years of experience. The company develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology using advanced ultrasound technology. With a robust presence worldwide through a network of corporate offices, subsidiaries, and distribution partners, EDAP TMS is committed to innovation and excellence.

EDAP TMS operates through three main divisions:

  • HIFU (High-Intensity Focused Ultrasound): This division focuses on the development and marketing of devices for the non-invasive destruction of tumors. Key products include Ablatherm, Ablatherm Fusion, and the Focal One, which is the latest addition designed for ideal focal therapy of localized prostate cancer.
  • ESWL (Extracorporeal ShockWave Lithotripsy): This division manufactures and services the Sonolith range of lithotripters, which are used for the treatment of kidney stones.
  • Distribution: This division markets complementary products such as lasers, micro-ultrasound systems, and other medical devices from third-party suppliers.

EDAP TMS is known for its strong patent portfolio thanks to continuous investment in research and development. The company collaborates with globally acclaimed medical research institutions to push the boundaries of medical technology. Financially, EDAP TMS reported a gross profit of EUR 24.4 million (USD 26.4 million) for the year ending December 31, 2023, reflecting a slight increase from the previous year. However, the gross profit margin declined due to inflationary pressures and investments in U.S. operations to support long-term revenue growth.

Recent achievements include the launch of the Focal One and strategic partnerships to expand its product reach. The company’s commitment to innovation and patient care makes it a significant player in the medical device industry.

Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) Announces CEO's Participation at Piper Sandler 35th Annual Healthcare Conference in New York, New York
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
conferences
-
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) reports strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year, record nine months HIFU revenues, and a clinical research collaboration with Mount Sinai. The company also placed two additional Focal One systems in the fourth quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.94%
Tags
-
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that CEO Ryan Rhodes will deliver a presentation and host investor meetings at the Jefferies London Healthcare Conference on November 14-16, 2023, in London.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
Rhea-AI Summary
EDAP TMS SA to release Q3 2023 financial results on November 9th and host conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
EDAP TMS SA CEO to present at Morgan Stanley and H.C. Wainwright conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.22%
Tags
conferences
-
Rhea-AI Summary
EDAP TMS reports record Q2 2023 revenues of EUR 14.3 million ($15.5 million) and strong growth in HIFU procedures
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) announced unaudited financial results for Q1 2023, with total revenue of EUR 14.8 million, a 13.8% increase compared to Q1 2022. The HIFU business revenue increased by 39.5% driven by the sale of six Focal One units. The LITHO business revenue improved due to the sale of four lithotripsy units. The Distribution business revenue decreased slightly. Gross profit margin was 40.8%, lower than the previous year due to investments in service and applications in the U.S. Operating expenses increased significantly to EUR 12.6 million, mainly due to the ongoing build-out of the U.S. team and non-recurring expenses related to the leadership succession plan. The company reported an operating loss of EUR 6.6 million and a net loss of EUR 7.5 million. Cash and cash equivalents were EUR 58.3 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags

FAQ

What is the current stock price of EDAP TMS SA (EDAP)?

The current stock price of EDAP TMS SA (EDAP) is $2.47 as of November 22, 2024.

What is the market cap of EDAP TMS SA (EDAP)?

The market cap of EDAP TMS SA (EDAP) is approximately 94.8M.

What does EDAP TMS SA specialize in?

EDAP TMS SA specializes in developing, manufacturing, and distributing minimally-invasive medical devices for urology using advanced ultrasound technology.

What are the main divisions of EDAP TMS SA?

The main divisions are HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution.

What products are included in the HIFU division?

The HIFU division includes products like Ablatherm, Ablatherm Fusion, and the Focal One for non-invasive tumor destruction.

What is the function of the ESWL division?

The ESWL division focuses on the manufacturing and servicing of the Sonolith range of lithotripters used for kidney stone treatment.

What type of products does the Distribution division market?

The Distribution division markets complementary medical products such as lasers, micro-ultrasound systems, and other third-party medical devices.

What recent achievements has EDAP TMS SA accomplished?

Recent achievements include the introduction of the Focal One for focal therapy of localized prostate cancer and strategic partnerships to enhance product reach.

How does EDAP TMS SA support its innovation?

EDAP TMS SA supports innovation through continuous investment in research and development and partnerships with internationally renowned medical research institutions.

What were the financial results for EDAP TMS SA in 2023?

In 2023, EDAP TMS SA reported a gross profit of EUR 24.4 million (USD 26.4 million), with a gross profit margin of 40.4%.

How does EDAP TMS SA maintain its market position?

The company maintains its market position by continuously innovating, expanding its patent portfolio, and forming strategic partnerships.

Who can be contacted for investor relations at EDAP TMS SA?

For investor relations, you can contact Blandine Confort at bconfort@edap-tms.com or John Fraunces at jfraunces@lifesciadvisors.com.

EDAP TMS SA

Nasdaq:EDAP

EDAP Rankings

EDAP Stock Data

94.80M
37.10M
42.37%
0.18%
Medical Distribution
Healthcare
Link
United States of America
Lyon